Stock Market News

Ultragenyx stock rises after FDA grants breakthrough therapy status for Angelman syndrome drug

Jun 27, 2025 - 14:06
 0
Ultragenyx stock rises after FDA grants breakthrough therapy status for Angelman syndrome drug
Read More

Tags:

Previous Article

Akzo Nobel to sell Indian unit to JSW Group for $1.6 bln, plans to buy back shares

Next Article

Jefferies initiates Armada Hoffler at “buy,” targets 31% upside on NAV discount

Related Posts

Ofgem Draft to test regulator’s support for UK grid investment demands

Ofgem Draft to test regulator’s support for UK grid inv...

Jun 16, 2025  0

European stocks edge higher as ceasefire holds; Trump attacks Powell again

European stocks edge higher as ceasefire holds; Trump a...

Jun 26, 2025  0

Kraft Heinz invests $3 billion in U.S. factories amid tariff challenges - Reuters

Kraft Heinz invests $3 billion in U.S. factories amid t...

May 14, 2025  0